The invention relates to novel antiviral active components of the general formula 1, pharmaceutical composition, antiviral medicament, method for prophylaxis and treatment of viral diseases, particularly caused by hepatisis C viruses (HCV). In the general formula 1

R1 represents hydrogen, optionally substituted C 1 -C 4 alkyl, C 6 cycloalkyl, aryl, ethoxycarbonyl, nitro group; R2 represents hydrogen; R3 represents N -mono-or N,N -disubstituted 1-methylene-piperidine-3-carboxamide of the general formula 1a or N -mono- or N,N -disubstituted 1-methylene-piperidine-4-carboxamide of the general formula 1b; R4 represents hydrogen, optionally substituted C 1 -C 3 alkyl; or R2 and R3 together with the C-atoms they are attached to form substituted ,3,4,9-tetrahydro-1 H -carbazole of the general formula 1.1, or R2, R3, and R4 together with the atoms they are attached to form substituted azaheterocycles of the eneral formula 1.2; R5 and R6 optionally identical represent hydrogen, optionally substituted C 1 -C 3 alkyl or C 3 -C 6 cydoalkyl, or R5 and R6 together with the N-atom they are attached to form optionally substituted 5- or 6- membered azaheterocyclyl comprising one or two N-atoms and optionally condensed with benzene ring;
R7 and R8 represent hydrogen or R7 and R8 together with the C-atom they are attached to form C=O group; R9 represents azaheterocyclyl comprising at least one N-atom, unsubstituted formamide, or phenyl substituted with ethoxycarbonyl or nitro group; R10 represents hydrogen, optionally substituted C 1 -C 3 alkyl, substituted acetyl; n = 1 or 2; solid line accompanied by the dotted line, i.e. ( ), represents single or double C-C bond.